Metabolic and cardiovascular (CV) diseases are among the major cause of death in Hungary and worldwide, thus impose an enormous social and economic burden. In the clinical practice there is a great need for i) the elucidation of the molecular pathomechanism of such high-burden diseases (including obesity, diabetes, heart failure), as well as for ii) the development of novel therapies, cost-effective treatments and iii) more personalized or at least targeted therapeutic approaches. This is especially true for the chronic, most often ageing related cardiovascular and metabolic diseases. As an example, due to landmark development of invasive technologies of the past century, the efficacy of successful clinical management of acute cardiovascular conditions (e.g. heart attack) has significantly improved. However, in parallel with an increase in life expectancy (largely due to the improved therapy of acute heart conditions mentioned above), the field now faces a serious problem of chronic cardiovascular diseases (such as e.g. chronic heart failure).
As these ageing related conditions are characterized by very complex pathomechanisms involving metabolic and immunological alterations, as well as subcellular, cellular and tissue remodeling, it is very important for research-oriented, industrial and governing bodies to realize that the mechanistic and/or molecular understanding of such high-burden diseases is at least as important for next generation medicine as are the direct conventional clinical treatment efforts. We are concerned that a better genetic, transcriptomic and molecular characterization of CV diseases is a key element of this process.